Published in J Clin Oncol on June 06, 2016
Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor. Oncotarget (2016) 0.92
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol (2017) 0.90
The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE". PLoS Med (2016) 0.83
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? Int J Mol Sci (2017) 0.78
Current and Emerging Applications of Droplet Digital PCR in Oncology. Mol Diagn Ther (2017) 0.76
Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells. Cancer Lett (2016) 0.76
Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer. Nat Genet (2017) 0.75
ESR1 mutations in breast cancer. Aging (Albany NY) (2017) 0.75
Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer. Front Oncol (2017) 0.75
Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers. Breast Cancer Res (2016) 0.75
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. Elife (2016) 0.75
Dissecting the Heterogeneity of Circulating Tumor Cells in Metastatic Breast Cancer: Going Far Beyond the Needle in the Haystack. Int J Mol Sci (2016) 0.75
Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal Hormone Receptor-Positive/HER2- Advanced Breast Cancer. Oncologist (2016) 0.75
A Cross-Sectional Comparison of Druggable Mutations in Primary Tumors, Metastatic Tissue, Circulating Tumor Cells, and Cell-Free Circulating DNA in Patients with Metastatic Breast Cancer: The MIRROR Study Protocol. JMIR Res Protoc (2016) 0.75
Antiestrogen Resistant Cell Lines Expressing Estrogen Receptor α Mutations Upregulate the Unfolded Protein Response and are Killed by BHPI. Sci Rep (2016) 0.75
Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: implications for reducing breast cancer mortality disparities. Breast Cancer Res Treat (2017) 0.75
Progress with palbociclib in breast cancer: latest evidence and clinical considerations. Ther Adv Med Oncol (2016) 0.75
Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients. Oncotarget (2017) 0.75
Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients. Transl Oncol (2017) 0.75
A Review of Fulvestrant in Breast Cancer. Oncol Ther (2017) 0.75
Structurally novel antiestrogens elicit differential responses from constitutively active mutant estrogen receptors in breast cancer cells and tumors. Cancer Res (2017) 0.75
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. Oncotarget (2017) 0.75
Liquid biopsy: unlocking the potentials of cell-free DNA. Virchows Arch (2017) 0.75
Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis. Oncogene (2017) 0.75